TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21228786

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg per day)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Perindopril/Indapamide (2/0.6 mg per day)
Number of subjects: 201
Study: 19856795

Group type: EXPERIMENTAL
Intervention: Test drug (500 mg azithromycin tablet - Zycin)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference drug (500 mg azithromycin)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Test drug (500 mg azithromycin tablet - Zycin) vs Reference drug (500 mg azithromycin)
Number of subjects: 18
Study: 17215752

Group type: EXPERIMENTAL
Intervention: Verum TENS
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham TENS (Control)
Number of subjects: 63
Study: 17145426

Group type: EXPERIMENTAL
Intervention: 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137)
Number of subjects: 275

Group type: COMPARATOR
Intervention: 100 mg aspirin daily alone (n = 138)
Number of subjects: 275
Study: 14523634

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 306
Study: 10618674

Group type: EXPERIMENTAL
Intervention: Caucasian group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Afro-Caribbean group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Caucasian group (adjusted for blood pressure)
Number of subjects: 41
Study: 7545577

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 12 IU/m2 per week
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 18 IU/m2 per week
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) after GH treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Testosterone (T) after GH treatment
Number of subjects: 39
Study: 1963014

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg subcutaneously twice daily for 14 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6217577

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day) for one month
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31619653

Group type: EXPERIMENTAL
Intervention: Ultra-High Hydrostatic Pressurizing Brown Rice (UHHPBR)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Polished White Rice (WR)
Number of subjects: 52
Study: 27999106

Group type: EXPERIMENTAL
Intervention: 10‐h overnight GCG infusion (6 ng/[kg × min]) followed by 3‐h infusion of GCG, octreotide (OCT), and insulin (INS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Overnight saline (SAL) infusion followed by GCG/OCT/INS infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Overnight saline (SAL) infusion followed by SAL/OCT/INS infusion
Number of subjects: 30
Study: 25260112

Group type: EXPERIMENTAL
Intervention: 30% maximum voluntary handgrip contraction
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 50% maximum voluntary handgrip contraction
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 70% maximum voluntary handgrip contraction
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 23448122

Group type: EXPERIMENTAL
Intervention: High-pressure laparoscopic cholecystectomy (HPLC) at 14 mm Hg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low-pressure laparoscopic cholecystectomy (LPLC) at 8 mm Hg
Number of subjects: 101
Study: 21255431

Group type: EXPERIMENTAL
Intervention: Iyengar yoga program (12 - 1.5 hour sessions twice weekly for 6 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 70
Study: 18050059

Group type: EXPERIMENTAL
Intervention: Strength training (20-week progressive strength training)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 74
Study: 16801514

Group type: COMPARATOR
Intervention: Prefabricated orthosis (firm foam)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Customized orthosis (semirigid plastic)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Sham orthosis (soft, thin foam)
Number of subjects: 135
Study: 12708641

Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest X-ray screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study: 10914850

Group type: EXPERIMENTAL
Intervention: Aerobic, weight bearing exercise program (3 times a week for 12 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Steroid treated groups (exercise vs usual care)
Number of subjects: 30
Study: 8616076

Group type: EXPERIMENTAL
Intervention: Autologous monoclonal IgG immunization
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Repeated immunization
Number of subjects: 5
Study: 1451521

Group type: EXPERIMENTAL
Intervention: Monophasic ethinylestradiol (EE)/desogestrel (DSG) OC
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Monophasic levonorgestrel (LNG) OC
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Triphasic levonorgestrel (LNG) OC
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All OCs
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cyclical symptom changes
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Women with 'pure' PMS
Number of subjects: 37
Study: 6364395

Group type: EXPERIMENTAL
Intervention: specially designed infant milk formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard modified infant milk formula
Number of subjects: 0
Study: 30506103

Group type: EXPERIMENTAL
Intervention: Online mindfulness-based intervention (MBI)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 69
Study: 29749363

Group type: EXPERIMENTAL
Intervention: Unani treatment (oral UNIM-401 and topical UNIM-403)
Number of subjects: 287

Group type: COMPARATOR
Intervention: PUVA sol
Number of subjects: 287
Study: 27528849

Group type: EXPERIMENTAL
Intervention: iPad with video
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: iPad with game
Number of subjects: 146

Group type: COMPARATOR
Intervention: no-iPad
Number of subjects: 146
Study: 24452673

Group type: COMPARATOR
Intervention: Sequential induction chemotherapy and radiotherapy (control)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (experimental)
Number of subjects: 450
Study: 20971655

Group type: EXPERIMENTAL
Intervention: CVD with cholinergic involvement (CVD-Ch(+))
Number of subjects: 502

Group type: COMPARATOR
Intervention: Non-CVD
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: CVD without cholinergic involvement (CVD-Ch(-))
Number of subjects: 502
Study: 20129231

Group type: EXPERIMENTAL
Intervention: Nutritional intervention aimed at portion control
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Self-weighing (regardless of group)
Number of subjects: 19
Study: 17331860

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study: 16280436

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 11689274

Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 436
Study: 9463180

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day for 6 months)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily for 6 months)
Number of subjects: 80
Study: 7949640

Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 6)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Famotidine (n = 13)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physiological saline (n = 15)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 7% sodium bicarbonate (n = 7)
Number of subjects: 41
Study: 3079582

Group type: EXPERIMENTAL
Intervention: Narrow excision (1-cm margins)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Wide excision (3-cm margins)
Number of subjects: 612
Study: 29659631

Group type: EXPERIMENTAL
Intervention: Paracetamol (1 gram) IV preoperatively followed by two postoperative doses 6 hours apart
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Paracetamol (1 gram) IV
Number of subjects: 50
Study: 27251517

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) administered under endoscopic therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Epinephrine (1/10,000) submucosally injected to ulcer margins
Number of subjects: 63
Study: 25248949

Group type: EXPERIMENTAL
Intervention: PBE with feldspathic ceramic (G1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PBE with resin nano-ceramic (G2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No PBE with feldspathic ceramic (G3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No PBE with resin nano-ceramic (G4)
Number of subjects: 48
Study: 23525983

Group type: EXPERIMENTAL
Intervention: 100 mg sitafloxacin once daily (100 mg qd group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50 mg sitafloxacin twice daily (50 mg bid group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 90
Study: 20637457

Group type: EXPERIMENTAL
Intervention: Flexible GnRH antagonist administration (started when LH >10 IU/L, or follicle >12 mm, or serum E(2) >150 pg/mL)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Fixed GnRH antagonist administration (started on day 6 of stimulation)
Number of subjects: 146
Study: 18946456

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 45
Study: 16499576

Group type: EXPERIMENTAL
Intervention: Intranasal vaccine delivery (OptiMist device, nasal drops)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Oral spray immunization
Number of subjects: 65
Study: 14584553

Group type: EXPERIMENTAL
Intervention: Impaired ability to retrieve events from the anterograde period
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Spared ability to retrieve events from the retrograde period
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: n-back task performance
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Episodic recognition memory task
Number of subjects: 1
Study: 10478148

Group type: EXPERIMENTAL
Intervention: Capillary zone electrophoresis (CZE)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Agarose gel electrophoresis (AGE)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Immuno-subtraction electrophoresis (ISE)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Immunofixation electrophoresis (IFE)
Number of subjects: 695
Study: 8917826

Group type: EXPERIMENTAL
Intervention: Barrier cream formulation 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Barrier cream formulation 2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Barrier cream formulation 3
Number of subjects: 6
Study: 1760699

Group type: EXPERIMENTAL
Intervention: Minimal surgery (under‐running the vessel or ulcer excision and adjuvant ranitidine)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional ulcer surgery (vagotomy and pyloroplasty or partial gastrectomy)
Number of subjects: 137
Study: 6981593

Group type: EXPERIMENTAL
Intervention: Iontophoretic application of Placenta‐Lucchini in combination with catalase and mucopolysaccharidase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra‐articular application of Placenta
Number of subjects: 0
Study: 31573855

Group type: EXPERIMENTAL
Intervention: Soft-tissue gas identified on postoperative radiography after TKA
Number of subjects: 204

Group type: COMPARATOR
Intervention: No soft-tissue gas identified on postoperative radiography after TKA
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Presence of soft-tissue gas on radiography 14 days after TKA
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Soft-tissue gas cases
Number of subjects: 204
Study: 28210935

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation (15 ml kg‐1 fluid in 30 min)
Number of subjects: 30
Study: 27804268

Group type: EXPERIMENTAL
Intervention: Canola oil diet
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CanolaOleic oil diet
Number of subjects: 101

Group type: COMPARATOR
Intervention: Flax/Safflower oil diet
Number of subjects: 101
Study: 24590751

Group type: EXPERIMENTAL
Intervention: Information explaining the lack of evidence that MMR causes autism from the CDC
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Textual information about the dangers of the diseases prevented by MMR from the Vaccine Information Statement
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Images of children who have diseases prevented by the MMR vaccine
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: A dramatic narrative about an infant who almost died of measles from a CDC fact sheet
Number of subjects: 1759

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1759
Study: 22903248

Group type: EXPERIMENTAL
Intervention: Intermittent pneumoperitoneum (IPP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Surgeon's perception of breaks
Number of subjects: 26
Study: 20423424

Group type: EXPERIMENTAL
Intervention: 4-day embedded academic learning support workshop
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 18690343

Group type: EXPERIMENTAL
Intervention: Thrombin generation measurement using Calibrated Automated Thrombogram (CAT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Thrombin generation measurement with thrombomodulin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Correlation analysis of protein C activity, protein S antigen, and free protein S with ETP
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Analysis of FVIII levels and thrombomodulin induced reduction of ETP and peak height
Number of subjects: 104
Study: 16219122

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medications alone
Number of subjects: 0
Study: 12211508

Group type: EXPERIMENTAL
Intervention: Dietary weight loss and exercise
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 316

Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 316
Study: 10519936

Group type: EXPERIMENTAL
Intervention: Hib-tetanus toxoid conjugate vaccine (Hib-T)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: DT- IPV mixed vaccine
Number of subjects: 287

Group type: COMPARATOR
Intervention: Subcutaneous administration
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (T) as a carrier protein
Number of subjects: 287
Study: 8821074

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2074087

Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2, 1 microgram/kg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: GHRH(1-44)NH2, 1 and 2 microgram/kg administered in random order
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: GHRH tests performed on 2 consecutive days
Number of subjects: 76
Study: 6947118

Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy at 4-week intervals
Number of subjects: 136

Group type: COMPARATOR
Intervention: Specific immunotherapy with neuraminidase-modified allogeneic blast cells
Number of subjects: 136
Study: 6418549

Group type: EXPERIMENTAL
Intervention: 5 g mezlocillin single-dose prophylaxis given immediately before surgery
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 5 g mezlocillin single-dose prophylaxis
Number of subjects: 358
Study: 29361442

Group type: COMPARATOR
Intervention: tDCS at 0.034 mA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tDCS at 1 mA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tDCS at 2 mA
Number of subjects: 100

Group type: COMPARATOR
Intervention: tDCS at 0.016 mA
Number of subjects: 100

Group type: COMPARATOR
Intervention: tDCS at 0 mA
Number of subjects: 100
Study: 28157084

Group type: EXPERIMENTAL
Intervention: Massage (15 minutes, twice a week for 4 weeks, total of 8 sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 50
Study: 24770625

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SB-649868
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23175341

Group type: EXPERIMENTAL
Intervention: Itraconazole, 200 mg daily for six weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (30 participants without clinical disorders)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Itraconazole treatment
Number of subjects: 36
Study: 20021706

Group type: EXPERIMENTAL
Intervention: Salient shared humanity with a benevolent human norm
Number of subjects: 186

Group type: COMPARATOR
Intervention: Salient shared humanity with a hostile human norm
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Salient shared humanity with a hostile human norm (when perpetrator intentions were unambiguously negative)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Salient shared humanity with a hostile human norm (when perpetrator intentions were ambiguous)
Number of subjects: 186
Study: 18606033

Group type: EXPERIMENTAL
Intervention: Head Start REDI intervention
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Initial EF
Number of subjects: 356
Study: 15787675

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11916372

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (Depakote) detoxification
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (Depakote) detox plus maintenance
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard benzodiazepine detoxification
Number of subjects: 16
Study: 10610014

Group type: EXPERIMENTAL
Intervention: Olestra group (1.5 servings/day of Pringles with olestra for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (1.5 servings/day of Pringles without olestra for 2 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 7793192

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine-scopolamine (0.15 +/- 0.006 mg x kg-1)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Rectal hydrogel of morphine-scopolamine (0.25 +/- 0.015 mg x kg-1)
Number of subjects: 205
Study: 1846876

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 8
Study: 7320363

Group type: EXPERIMENTAL
Intervention: Modularized stress reduction packet
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 299
Study: 31481364

Group type: EXPERIMENTAL
Intervention: Personalised Risk Report embedded in the electronic health record, printed with auto‐filled results, used as a discussion aid during the NHS Health Check.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Personalised Risk Report
Number of subjects: 18
Study: 28316118

Group type: EXPERIMENTAL
Intervention: Late preterm infants
Number of subjects: 118

Group type: COMPARATOR
Intervention: Full-term infants
Number of subjects: 118
Study: 25597457

Group type: COMPARATOR
Intervention: Trained control group (TDT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trained study group (SSDT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nontrained groups (TDNT and SSDNT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 39
Study: 23463483

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg · kg(‐1)
Number of subjects: 16
Study: 20848578

Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group Exercise Therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 18796139

Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Number of subjects: 4500
Study: 16942980

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 12641635

Group type: EXPERIMENTAL
Intervention: 50 mg progesterone intramuscularly (i.m.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 300 micro g desogestrel orally daily for 7 days
Number of subjects: 20
Study: 11300427

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9262495

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g per day) during lactation
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo during lactation
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g per day) after weaning
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo after weaning
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g per day)
Number of subjects: 383
Study: 8120154

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3632762

Group type: EXPERIMENTAL
Intervention: Fish oil (1.5 g oil/10 kg b.wt./day for three weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Olive oil (1.5 g oil/10 kg b.wt./day for three weeks)
Number of subjects: 21
Study: 29559294

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: External cold and vibration
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control
Number of subjects: 121
Study: 28347292

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0